BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Closed|| Long (1Y)
Angel Broking maintains buy on Aurobindo Pharma
Angel Broking says sales and operating profit margins were mostly in line with the expectations. The sales growth during the quarter was aided by the formulation sales (80 per cent of the sales), which posted a growth of 19.6 per cent, while API, which constituted around 20 per cent of sales posted a growth of 14.5 per cent.